Sec Form 4 Filing - RAUSCH CARL W @ Boston Therapeutics, Inc. - 2017-08-14

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person RAUSCH CARL W 2. Issuer Name and Ticker or Trading Symbol Boston Therapeutics, Inc. [ BTHE] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Executive Officer (Last) (First) (Middle) C/O BOSTON THERAPEUTICS, INC., 354 MERRIMACK STREET, #4 3. Date of Earliest Transaction (MM/DD/YY) 08/14/2017 (Street) LAWRENCE, MA01843 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series A Preferred Stock ( 2 ) $ 0.1 08/14/2017 P 1,000,000 08/14/2017 ( 2 ) Common Stock 1,000,000 $ 0.1 1,000,000 D Common Stock Purchase Warrants ( 2 ) $ 0.15 08/14/2017 P 2,000,000 08/14/2017 08/14/2022 Common Stock 2,000,000 $ 0.15 2,000,000 D Series A Preferred Stock ( 2 ) $ 0.1 02/02/2018 P 1,000,000 02/02/2018 ( 2 ) Common Stock 1,000,000 $ 0.1 1,000,000 D Common Stock Purchase Warrants ( 2 ) $ 0.15 02/02/2018 P 2,000,000 02/02/2018 02/02/2023 Common Stock 2,000,000 $ 0.15 2,000,000 D Stock Options ( 1 ) $ 0.2 08/12/2016 08/12/2021 Common Stock 6,000,000 6,000,000 D Stock Options $ 0.18 03/25/2015 08/12/2026 Common Stock 500,000 500,000 D Stock Options $ 0.1 09/15/2011 08/12/2026 Common Stock 1,500,000 1,500,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other RAUSCH CARL W C/O BOSTON THERAPEUTICS, INC. 354 MERRIMACK STREET, #4 LAWRENCE, MA01843 X Chief Executive Officer Signatures /s/ Carl W. Rausch 02/12/2018 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The options vest in three equal tranches of 2,000,000 upon the Company the Company raising $1,000,000 in financing, the Company raising $5,000,000 in financing and the Company entering into a significant corporate alliance for substantial marketing and selling of the Company's product portfolio. The initial tranche is exercisable at $0.20 per share, the second tranche will be $0.40 per share and the third tranche will be $0.60 per share, which such vesting is subject to continued employment as an executive with the Company as of the vesting date. The expiration date is five years from the date of grant. ( 2 )On August 14, 2017 and February 2, 2018, World Technology East II Limited ("WTE") acquired 10,000 shares of Series A Preferred Stock and common stock purchase warrants to acquire 2,000,000 shares of common stock on each date. Mr. Rausch and Conroy Cheng each equally control WTE and share dispositive and voting control over such securities.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.